Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases

  • Eur J Med Chem. 2019 Nov 1:181:111569. doi: 10.1016/j.ejmech.2019.111569.
David Vanda  1 ,  Paweł Zajdel  2 ,  Miroslav Soural  3
Affiliations
  • 1. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00, Olomouc, Czech Republic.
  • 2. Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna, 30-688, Kraków, Poland. Electronic address: [email protected].
  • 3. Department of Organic Chemistry, Faculty of Science, Palacký University, 17. listopadu 12, 771 46, Olomouc, Czech Republic. Electronic address: [email protected].
PMID: 31404862 DOI: 10.1016/j.ejmech.2019.111569
Abstract

This article provides an overview of compounds based on imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine, imidazo[4,5-b]pyridine and imidazo[4,5-c]pyridine scaffolds, which act as potent ligands of diverse molecular targets localized in the central nervous system. A literature survey revealed that various imidazopyridines can be powerful modulators of several diseases associated with CNS dysfunction including Alzheimer's disease, Parkinson's disease, schizophrenia, depression or sleeping disorders. A description of target Enzymes (e.g., β-secretase, γ-secretase, fatty acid amide hydrolase - FAAH, leucine-rich repeat kinase 2 - LRRK2) and selected receptors (e.g., GABA-A, histamine H3, serotonin 5-HT3, 5-HT4, 5-HT6, dopamine D4, adenosine A2A, orexin), modes of action of imidazopyridine-based ligands and their therapeutic importance is discussed.

Keywords
Imidazo[1,2-a]pyridine; Imidazo[1,5-a]pyridine; Imidazo[4,5-b]pyridine; Imidazo[4,5-c]pyridine; Neurodegenerative disorders; Neurological disorders; Sleeping disorders.
Products